COVID Severity Test for HCP | EpiSwitch® CST COVID-19 Severity Test for SARS-CoV-2

EpiSwitch COVID Severity Test (CST) is an advanced blood test that will

help your patients understand their risk of a severe immune response to COVID-19.

Watch video to learn more
EpiSwitch CST assesses the risk that
COVID-19 poses to an individual.

EpiSwitch CST is the first and only commercially-available blood test for the prediction of COVID-19 severity in ANY adult, independent of COVID-19 status. The test can help patients understand - and cope - with their individual level of risk.

EpiSwitch CST is designed to provide healthcare professionals (HCPs) and their adult patients with actionable, decision-making information regarding infection mitigation during the COVID-19 pandemic based on the unique 3D genetic immune profile of each individual.

The test is variant-agnostic so it identifies risk due to regular SARS-CoV-2, as well as delta, omicron, and other strains.

How EpiSwitch CST can help

Effective risk management with guidance from EpiSwitch CST.

ENHANCED, PERSONALIZED GUIDANCE

EpiSwitch CST delivers critical information based on genetic markers to aid in determining an individual’s level of risk. While age and known pre-existing conditions are a proxy for risk, such population-based metrics may or may not apply to a given individual.

PREDICT RESPONSE TO INFECTION IN ANY ADULT

EpiSwitch CST helps identify individuals who would most likely have a severe immune response, independent of their COVID-19 status––including those never infected, those who have been infected, and those who are currently infected.

HIGH CONFIDENCE FOR HCPs

EpiSwitch CST offers high sensitivity and specificity to predict immune response by measuring six genetic markers to assign an individual to a risk category.

FAST RESULTS

Order an EpiSwitch CST blood test today and get results in 48-72 hours.


EpiSwitch CST provides HCPs with an
easy-to-understand molecular assessment of risk for a severe immune response to COVID-19.

Interpreting the EpiSwitch CST report

Personalize your guidance for each patient.

The EpiSwitch CST report includes clear guidance for HCPs to interpret an adult patient’s risk score and formulate an effective management plan.

Individuals with a high-risk EpiSwitch CST score are at increased probability of experiencing a severe immune response to COVID-19. Such individuals should be counseled on their risk level and may benefit from a mitigation-strategy review to avoid infection. In the event of infection, early use of medications or other interventions are recommended.

Those at average risk should not be construed as having no risk; complications that do not require critical care are possible.

Risk results do not provide information about an individual’s risk of becoming infected. Regardless of risk results, government and local health-department guidelines must be followed to avoid transmitting the virus.

Features of EpiSwitch CST

A validated prognostic tool for predicting a severe immune response to
COVID-19.

EpiSwitch CST measures six genetic markers to determine risk category. EpiSwitch CST was developed using epigenetic data obtained from COVID-19 patients in North America, South America, and Europe.

Accuracy:
88%
Positive Predictive Value:
93%
Sensitivity:
88%
Negative Predictive Value:
80%
Specificity:
88%

EpiSwitch CST Provider Guide

Learn how the test can help you provide evidence-based guidance to your patient.

Become an EpiSwitch CST testing center or a registered EpiSwitch CST healthcare provider

Are you interested in becoming an EpiSwitch CST testing center or a registered EpiSwitch CST healthcare provider?
Contact EpiSwitch CST Customer Service at 888-236-8896 to open an account, request customized EpiSwitch CST Requisition Forms custom-branded for your practice, order EpiSwitch CST processing kits, or request further assistance relating to EpiSwitch CST. We look forward to speaking with you.

Order EpiSwitch CST

Download the Test Requisition Form and order a test for your adult patients

Provider FAQ